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Introduction/Objective. In the present paper, we aimed to test the value of the red cell distribution width (RDW) coefficient of
variation as a candidate biomarker for pulmonary arterial hypertension (PAH) in patients with connective tissue disorders
(CTD), correlating it with the degree of cardiopulmonary impairment in these patients. Methods. The study population included
N = 141 patients with CTD and N = 59 patients affected by pulmonary hypertension of other etiologies, all referred to the
Pulmonary Hypertension Clinic of the Cardiology Division of an Academic Hospital in Northern Italy for evaluation (including
right catheterization). Clinical, instrumental, and laboratory data were collected and related to RDW and other full blood count
indexes. Results. Twenty out of 141 CTD patients (14%) received a diagnosis of PAH. In comparison to those without PAH,
CTD patients with PAH displayed a larger RDW (14.9% (13.5-17.2) vs. 13.8% (13.1-15.0); p = 0 02) and a lower platelet count
(205 177‐240 × 109/l vs. 244 197 5‐304 2 × 109/l; p = 0 005). Moreover, with respect to CTD patients without PAH, RDW
was significantly larger also in PH of other etiologies. In contrast, the platelet count was significantly lower only in CTD-related
PAH, with a value > 276 × 109/l being 100% sensitive in ruling out PAH. Finally, RDW, but not the platelet count, was related
directly to systolic pulmonary arterial pressure (r = 0 381; p = 0 0008) and right ventricle diameter (r = 0 283; p = 0 015) and
inversely to diffusing capacity of the lung for carbon monoxide (r = −0 325; p = 0 014). Conclusion. RDW is a promising
candidate biomarker for the screening and the prognostic stratification of PAH in CTD patients.
1. Introduction
Pulmonary hypertension (PH) is a clinical entity that com-
prises multiple conditions of different etiologies and patho-
physiology, defined by the presence of a mean pulmonary
arterial pressure (mPAP) equal to or greater than 25mmHg,
measured during invasive right heart catheterization (RHC)
at rest [1]. Although reliable estimates of prevalence are
lacking, PH as defined above is not uncommon. Group 1
PH (i.e., pulmonary arterial hypertension (PAH), character-
ized by a pulmonary artery wedge pressure ≤ 15mmHg), on
the other hand, is a rare disease that may complicate connec-
tive tissue diseases (CTD) [2]. The estimated prevalence and
incidence of PAH are around 15-60 cases and 5-10 cases per
million adult population, respectively [3]; roughly, half of
these cases occur in association with CTD, with a prevalence
of 21-29% in mixed connective tissue disease (MCTD), up to
14% systemic lupus erythematosus (SLE) [4], and close to
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20% in systemic sclerosis (SSc) [5]. Lower rates have been
reported in Sjogren’s syndrome (SS) [4] and in dermatomyo-
sitis/polymyositis (PM/DM) [6].
Consensus exists that these high-risk patients should be
screened for PAH, since CTD-related PAH has a severe prog-
nosis, even poorer than the idiopathic form [7]; in fact, PAH
is the leading cause of death in systemic sclerosis [8]. More-
over, early treatment of PAH patients leads to improved out-
comes, whereas treatment delay is associated with clinical
worsening [9]. The screening strategy most used today is
based on the application of a two-step algorithm (DETECT)
on systemic sclerosis patients, which is 97% sensitive and
35% specific for the diagnosis of PAH [10]. Despite the rela-
tively good performance of the DETECT algorithm, no uni-
versally agreed approach by which to screen these patients
exists, and novel biomarkers of PAH are actively pursued.
The red cell distribution width (RDW) coefficient of var-
iation, a measure of the variability in size of circulating eryth-
rocytes, is routinely reported as a component of the complete
blood count and has been used in the differential diagnosis of
anemia [11]. Recently, RDW has been shown to stratify prog-
nosis among patients with idiopathic and thromboembolic
PAH [12, 13]. Moreover, RDW has been proposed as a pre-
dictor of PAH in SSc and in SS [14, 15].
In the present paper, we aimed to evaluate RDW as a can-
didate biomarker for PAH in CTD patients and to correlate it
with the severity of cardiopulmonary impairment.
2. Methods
2.1. Patients. We performed a cross-sectional observational
study. FromOctober 1st, 2016, toApril 20th, 2018,we recruited
141 consecutive patients, affected by CTD and referred to the
PulmonaryHypertensionOutpatient Clinic of the Cardiology
Department, A.O.U. “Maggiore della Carità,” Novara, Italy.
We applied the following exclusion criteria:
(a) Age < 18 years
(b) Refusal to participate in the study
(c) Impossibility to undergo the required cardiopulmo-
nary assessment
We also recruited 59 patients affected by PH of other eti-
ologies, applying the same exclusion criteria, to checkwhether
the predictive factors identified in CTD-related PAH were
valid in other clinical settings.
2.2. Main Outcome Variable. Following echocardiography
estimation of systolic pulmonary artery pressure (sPAP),
right heart catheterization (RHC) was performed to con-
firm PH, when appropriate. PAH was defined by mean
pulmonary artery pressure mPAP ≥ 25mmHg, pulmonary
capillary wedge pressure ≤ 15mmHg, and pulmonary
vascular resistance > 3WoodUnits. Whenever contraindi-
cations to RHC occurred, PH was diagnosed based on
echocardiography-estimated sPAP ≥ 35mmHg and addi-
tional high-probability criteria, according to 2015 ESC/ESR
guidelines. In the control group, PH etiology was carefully
searched for, and patients were classified according to the
Nice 2013 criteria [1].
2.3. Procedures. All patients underwent a comprehensive
medical history and a thorough physical examination,
aimed at assessing the presence and severity of signs and
symptoms compatible with PH. Cardiovascular risk factors
and other comorbidities were investigated. Past medical his-
tory and drug history were recorded. Rheumatologic disease
history was recalled through an extensive review of the
medical records.
Complete blood count (CBC), serum creatinine, C-
reactive protein (CRP), and brain natriuretic peptide (BNP)
were measured. The serum autoantibody profile was exam-
ined. Further assessment of these patients consisted of
(i) 12-lead electrocardiogram with 6 limb and 6 precor-
dial leads with paper speed set at the standard rate of
25mm/s
(ii) six-minute walking distance (6MWD), which mea-
sures the distance that the patient could quickly walk
over a total of six minutes on a hard, flat surface
(iii) posteroanterior and lateral chest X-rays and, when
necessary, high-resolution computed tomography
(HRCT) (to rule out interstitial lung disease)
(iv) pulmonary function tests (PFTs), performed on
the same day the patient attended the PH clinic.
The spirometry was performed using standardized
equipment and technique with a spirometer, which
measured the amount of air the subject exhaled
and the rate at which it was exhaled. The device
was connected to a computer employing “Medisoft
ExpAir 1.28.20” to convert the signals into numeri-
cal values and graphics. The following standardized
measurements were evaluated: forced vital capacity
(FVC), forced expiratory volume in the 1st second
(FEV1), FEV1/FVC (%) (also known as the Tiffe-
neau index)
(v) the diffusing capacity of the lung for carbon monox-
ide (DLCO), measured with the single-breath Jones-
Meade protocol. Once the mouthpiece and the nose
clip were in place, the subject made a maximal expi-
ration and then, with a maximal inspiration, inhaled
a gas blend containing carbon monoxide (0.3%) and
other inert gases (0.3% CH4). Then, the patient was
asked to hold his/her breath for about 10 seconds
and exhale afterwards. During the expiration, alveo-
lar air was analyzed: the ratio between carbon mon-
oxide in inspired gas and carbon monoxide in
exhaled air determined the diffusion of carbon
monoxide. Predicted DLCO corrected for haemo-
globin and alveolar volume was assessed
(vi) transthoracic echocardiography, performed using
the Vivid 7 or E9 cardiovascular ultrasoundmachine
by GE Medical Systems (Horten, Norway) with a
1.7/3.4MHz tissue harmonic transducer. All data
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were obtained in standardized patient positions,
according to the guidelines of the American Echo-
cardiography Society. The exam was performed by
an echocardiography expert in PH. The following
parameters were studied [16]: sPAP, right atrium
area (RAA), right ventricle diameter (RVD), and left
ventricular ejection fraction (LVEF). LVEF has been
evaluated with the modified Simpson method; sys-
tolic pulmonary artery pressure (sPAP) was esti-
mated from the maximal velocity of tricuspid
regurgitation (TR) and RAP (right atrial pressure)
using Bernoulli’s equation (sPAP = 4TR2 + RAP).
RAP was estimated with the respiratory motion
and the size of the inferior vena cava (IVC) from
the subcostal view. TR jet was graded according to
recommendations for the quantification of native
valvular regurgitation
(vii) right ventricle systolic function was evaluated by
estimating the Tricuspid Annular Plane Systolic
Excursion (TAPSE)
The study protocol was approved by the institutional eth-
ical committee and conducted in strict accordance with the
principles of the Declaration of Helsinki. Informed consent
was obtained from all individual participants included in
the study.
2.4. Statistical Analysis. Anthropometric, clinical, and bio-
chemical data were recorded in a database and analyzed by
the statistical software package MedCalc v.18.10.2 (MedCalc
Software, Broekstraat 52, 9030, Mariakerke, Belgium). The
measures of centrality and dispersion of data chosen were
medians and interquartile range (IQR). Continuous vari-
ables were compared between groups by the Mann–Whitney
and Kruskal-Wallis (K-W) tests. Exact Fischer’s test and
Pearson’s χ2 test were used, as appropriate, to explore the
associations of categorical variables. To test the diagnostic
performance of RDW and platelet count, receiver operating
characteristic curves were built, with calculation of the
respective areas under the curve (AUC). The level of signif-
icance chosen for all statistical tests was 0.05 (two-tailed).
3. Results
Among the 141 patients with CTD, the following diagnoses
were recorded: SSc (N = 102, 72.3%), SLE (N = 3, 2.1%), SS
(N = 1, 0.7%), PM/DM (N = 13, 9.3%), MCTD (N = 10,
7.1%), and undifferentiated CTD (UCTD; N = 12, 8.5%).
Out of 141, N = 20 received a diagnosis of PAH (14%): in
N = 10 patients, the diagnosis was based on RHC data.
In Table 1, we report the main features of these patients,
as well as the comparison between patients with and without
PAH. As shown in the table, the patients with PAH were
older and characterized by a significantly higher BNP and
sPAP; moreover, the creatinine clearance and the DLCO
were significantly lower in the case of PAH. Interestingly,
PAH was also associated with a larger RDW and a lower
platelet count. We therefore analyzed the diagnostic accuracy
of RDW and PLTs; in Figure 1, we report the respective ROC
curves. An RDWvalue ≥ 16% was 40.0% sensitive and 88.3%
specific for the diagnosis of PAH, with an AUC 0.666
(CI95%: 0.581-0.783; p = 0 015). A platelet count ≤ 276 ×
109/l was 100.0% sensitive and 36.3% specific for the diag-
nosis of PAH, with an AUC 0.697 (CI95%: 0.614-0.771;
p = 0 0001). 5/20 patients were affected by chronic respira-
tory failure requiring continuous oxygen supplementation.
This subset of patients had a trend, though not statistically
significant, towards a larger RDW (17.7% (15.4-18.2) vs.
14.2% (13.4-16.0)) when compared to those with PAH and
no chronic respiratory failure. Platelet count was not differ-
ent between groups (data not shown).
Table 1: Main features of the study population and differences related to the presence of PAH. We report the main features of the whole
study population; moreover, we compared CTD alone and CTD complicated by PAH. Categorical variables are shown as frequencies
(%); continuous variables are shown as medians (IQR). Mann–Whitney and Fisher’s exact tests were used as appropriate.
Variables Entire CTD population (N = 141) CTD without PAH (N = 121) CTD with PAH (N = 20) p
Age (years) 68 (57-76) 62 (52-72) 74 (69-79) 0.0001
Gender (F/M) 127 (90.1)/14 (9.9) 110 (90.9)/11 (9.1) 17 (85.0)/3 (15.0) 0.42
Hb (g/dl) 12.9 (11.8-14.0) 12.9 (11.7-13.8) 12.0 (11.6-13.8) 0.35
RDW (%) 14.0 (13.2-15.5) 13.8 (13.1-15.0) 14.9 (13.5-17.2) 0.02
PLTs (×109/l) 228 (190-295) 244 (197.5-304.2) 205 (177-240) 0.005
BNP (pg/ml) 78.7 (35.3-182.1) 52.1 (29.7-102.2) 204.9 (81.0-465.5) <0.0001
Creatinine clearance (ml/min) 82.5 (60.0-97.5) 89.0 (71.5-102.0) 65 (49.0-78.0) 0.0005
DLCO (ml/min/mmHg) 72.5 (52.0-87.0) 76.0 (64.0-87.2) 45.0 (40.2-54.7) <0.0001
FEV1 (%) 96.0 (78.0-113.0) 101.0 (84.7-115.0) 103.0 (87.5-115.0) 0.98
FEV1/FVC (%) 107.0 (101.0-114.0) 109.0 (102.5-115.5) 107.0 (102.0-111.0) 0.41
sPAP (mmHg) 33 (25-45) 27 (23-31) 46 (42-57) <0.0001
LVEF (%) 61.5 (57-66) 63.0 (59.0-67.0) 61.5 (55.5-65.5) 0.15
N : number; CTD: connective tissue diseases; PAH: pulmonary arterial hypertension; Hb: haemoglobin; RDW: red cell distribution width; PLTs: platelets;
BNP: brain natriuretic peptide; DLCO: diffusion lung capacity for carbon monoxide; FEV1: forced expiratory volume in the 1st second; FVC: forced vital
capacity; sPAP: systolic pulmonary artery pressure; LVEF: left ventricular ejection fraction.
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We further tried to evaluate whether the increase in
RDW and the decrease in platelet count were limited to
CTD-related PAH or generalizable to other PH patients. In
Table 2, we report the main features of the PH control group
(Figure 2). With respect to CTD not complicated by PAH,
RDW was significantly higher in both CTD-related PAH
(14.9% (13.5-17.2)) and PH of other etiologies (14.8%
(13.2-17.0); K-W 13.6; p < 0 001). On the contrary, the plate-
let count was significantly lower only in CTD-related PAH
(205 177‐240 × 109/l; K-W 7.30; p = 0 02), being similar
between PH of other etiologies (222 184‐266 × 109/l) and
CTD not complicated by PAH (242 194‐302 × 109/l) (see
also Figure 2).
Finally, we evaluated the correlations between RDW
and platelet count measured in patients with PH and differ-
ent clinical and instrumental parameters. In Table 3, we
report the results of this analysis. Platelet count was not
related to any of the functional and echocardiographic
markers analyzed. On the contrary, RDWwas inversely asso-
ciated with DLCO and directly related to sPAP and right ven-
tricle diameter.
4. Discussion
The results of the present study indicate that RDW, a simple
parameter routinely obtained with the automated full blood
count, may be of help in the diagnostic evaluation and prog-
nostic stratification of CTD patients, with a specific focus on
PAH. These data will be discussed at the light of the existing
literature on the topic.
The rationale of the present study stems from previous
reports, suggesting that red blood cells and platelets are pos-
sibly involved in the pathogenesis of several inflammatory
diseases and may serve as diagnostic and prognostic bio-
markers in this context [17]. Growing attention has been
paid recently towards the prognostic implication of an
increased RDW: in fact, this parameter has been used as an
indicator of ineffective red cell production or haemolysis
but has recently been identified as a predictor of poor
prognosis in different cardiovascular and noncardiovascular
diseases [18, 19]. With specific regard to PH, a high RDW
predicts a poor prognosis in chronic thromboembolic PH
and in PAH [12, 13] and may be a factor in CTD-related
PAH, at least in Asian patients [14, 15]. Furthermore, in
SSc patients, a higher RDW has been observed in those
subjects with at least one clinical vascular involvement
(acral ulcers, PAH, or renal crisis) [20]. Our data confirm







































Figure 1: Receiver operating characteristic (ROC) curves for red cell distribution width (RDW) coefficient of variation and platelet count. In
(a), we report the ROC curve of RDW for the diagnosis of PAH; in (b), we report the ROC curve of platelet count for the diagnosis of PAH.
Table 2: Main features of the PH control group.We report the main
features of the control group with PH of other etiologies. Categorical
variables are shown as frequencies (%); continuous variables are
shown as medians (IQR).




Age (years) 73 (64-79)
Gender (F/M) 33 (56)/26 (44)
Hb (g/dl) 12.9 (11.9-14.8)
RDW (%) 14.8 (13.2-17.0)
PLTs (×109/l) 222 (184-266)
BNP (pg/ml) 182.5 (77.7-299.5)
Creatinine clearance (ml/min) 70.0 (51.0-87.0)
DLCO (ml/min/mmHg) 53.0 (42.0-80.0)
FEV1 (%) 70.0 (57.0-89.5)
FEV1/FVC (%) 102.0 (93.2-111.0)
sPAP (mmHg) 53 (44-69)
LVEF (%) 60 (55-66)
N : number; class 1: pulmonary arterial hypertension; class 2: PH related to
left heart disease; class 3: PH related to pulmonary disease; class 4:
thromboembolic PH; class 5: others; Hb: haemoglobin; RDW: red cell
distribution width; PLTs: platelets; BNP: brain natriuretic peptide; DLCO:
diffusion lung capacity for carbon monoxide; FEV1: forced expiratory
volume in the 1st second; FVC: forced vital capacity; sPAP: systolic
pulmonary artery pressure; LVEF: left ventricular ejection fraction.
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that RDWmay predict the presence of PAH in CTD patients;
moreover, RDWhas a potential prognostic implication, given
its association with sPAP, right ventricular size, and DLCO,
which are well-known prognostic markers in SSc-related
PAH [21, 22]. We finally showed that RDW is elevated in
PH belonging to classes different from class 1, therefore
marking more generally PH rather than PAH in CTD. The
reason why RDW is elevated under these circumstances is
still unknown, although it might reflect the microvascular
damage or the chronic inflammatory state, since elevation
of RDW levels was shown to reflect the circulating levels of
proinflammatory cytokines, such as tumor necrosis factor
α, interleukin- (IL-) 1, and IL-6 [20].
We also reported a significantly lower platelet count in
CTD patients with PAH; this observation might be explained
by an intravascular thrombosis due to endothelial damage,
leading to the local consumption of platelets [23]. However,
a low platelet count seems to be more specifically associated
with CTD-related PAH, since it was not observed in patients
with other forms of PH and in those with uncomplicated
CTD. Given that the platelet count was not associated with
other important prognostic markers of PAH but has high
sensitivity, its role may consist in the possibility of ruling
out PAH, when above the threshold indicated.
It might be argued that the increased RDW and reduced
platelet count belong to the development of hypoxia, leading
to increased erythropoiesis at the expense of megakaryopoi-
esis. We have no data about blood gas analysis of our
patients; however, those on oxygen supplementation because
of chronic respiratory failure were not characterized by a dif-
ferent platelet count. However, a trend towards a larger RDW
was observed. Hypoxia is, therefore, an intriguing potential
explanation of these associations, deserving consideration
in further studies.
A main limitation of the present study is related to the
small sample size of our cohort which, being representative
of a relatively rare complication of a rare disease, allowed
us to enrol only 20 patients with CTD-related PAH. This
significantly limits our possibility to draw definitive conclu-
sions, particularly with regard to the identification of diag-
nostic thresholds. Therefore, the ROC curves presented
have the value of an exploratory analysis, requiring confirma-
tion in larger cohorts.
Finally, for the present study, the diagnosis of PAH was
based on the 2015 ESC/ESR guidelines which defined pul-
monary arterial hypertension in the presence of a mPAP ≥







































Figure 2: RDW and platelet values according to underlying diagnosis. The box and whiskers of RDW (a) and platelet (b) values according to
the underlying diagnosis. RDW: red cell distribution width; PLTs: platelets; CTD: connective tissue diseases; PAH: pulmonary arterial
hypertension.
Table 3: Correlation between functional parameters and RDW and
platelet count in patients with PAH.
Variable RDW Platelet count
6MWD r = ‐0 051; p = 0 71 r = 0 021; p = 0 88
BNP r = 0 045; p = 0 69 r = 0 006; p = 0 96
Creatinine clearance r = ‐0 009; p = 0 94 r = 0 213; p = 0 06
Hb r = ‐0 331; p = 0 002 r = ‐0 031; p = 0 79
sPAP r = 0 381; p = 0 0008 r = 0 071; p = 0 54
LVEF r = 0 089; p = 0 45 r = 0 182; p = 0 12
RAA r = 0 199; p = 0 10 r = ‐0 081; p = 0 50
RVD r = 0 283; p = 0 015 r = ‐0 038; p = 0 75
DLCO r = ‐0 325; p = 0 014 r = 0 037; p = 0 79
FEV1 r = ‐0 179; p = 0 17 r = ‐0 169; p = 0 20
FEV1/FVC r = ‐0 152; p = 0 25 r = ‐0 188; p = 0 15
RDW: red cell distribution width; 6MWD: 6-minute walking distance; BNP:
brain natriuretic peptide; Hb: haemoglobin; sPAP: systolic pulmonary artery
pressure; LVEF: left ventricular ejection fraction; RAA: right atrium area;
RVD: right ventricle diameter; DLCO: diffusion lung capacity for carbon
monoxide; FEV1: forced expiratory volume in the 1st second; FVC: forced
vital capacity.
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2018 PHWorld Symposium. The new proposed definition of
PAH is based on the detection of amPAP ≥ 20mmHg with a
pulmonary vascular resistance ≥ 3WU at RHC [24]. Our
findings do not automatically extend to those patients with
a mPAP 21-24mmHg and, therefore, need to be confirmed
using this new diagnostic threshold.
5. Conclusions
In conclusion, RDW is a promising tool for the screening and
the prognostic stratification of PAH in CTD patients; its role
in complementing and refining the approach by which we
currently screen for PAH on these high-risk patients is worth
to be established in future studies.
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